AbCellera Biologics (ABCL) Other Non-Current Assets (2020 - 2026)

AbCellera Biologics has reported Other Non-Current Assets for 7 years, with the latest figure at $69.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 12.3% year-over-year to $69.1 million; the trailing twelve-month figure through Mar 2026 stood at $69.1 million (up 12.3% YoY), and the FY2025 full-year result was $51.9 million, up 90.29% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $69.1 million, up from $51.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $134.2 million in Q3 2024, with the low at $1.8 million in Q2 2022.
• Historically, Other Non-Current Assets has averaged $55.3 million across 5 years, with a median of $51.9 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 88.56% — and 2023, when it soared 1270.61%.
• AbCellera Biologics' Other Non-Current Assets stood at $46.3 million in 2022, then surged by 103.41% to $94.2 million in 2023, then tumbled by 71.03% to $27.3 million in 2024, then jumped by 90.29% to $51.9 million in 2025, then surged by 33.09% to $69.1 million in 2026.
• The last three Other Non-Current Assets figures came in at $69.1 million (Q1 2026), $51.9 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.